The development of COX2 inhibitors

Nature Reviews Drug Discovery

Volumn 2, Issue 3, 2003, Pages 179-191

  Flower, Rod J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FLOSULIDE; FLUFENAMIC ACID; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYPHENBUTAZONE; PARACETAMOL; PHENACETIN; PHENYLBUTAZONE; PIROXICAM; PROSTAGLANDIN INHIBITOR; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SALICYLIC ACID; UNINDEXED DRUG; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

DIGESTIVE SYSTEM ULCER; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RETROSPECTIVE STUDY; REVIEW; ANIMAL; DRUG DESIGN; METABOLISM; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037364161     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1034     Document Type: Review

References (143)

1. Analysts Rx Product Desk Reference (Merrill Lynch, London, 2001).
2. Smith, M. J. & Dawkins, P. D. Salicylate and enzymes. J. Pharm. Pharmacol. 23, 729-744 (1971).
3. Collier, H. O. J. A pharmacological analysis of aspirin. Adv. Pharmacol. Chemother. 7, 333-405 (1969).
4. Vane, J. R. Prostaglandins and the aspirin like drugs. Hosp. Pract. March, 61-71 (1972).
5. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231, 232-235 (1971).
6. Ferreira, S. H., Moncada, S. & Vane, J. R. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat. New Biol. 231, 237-239 (1971).
7. Smith, J. B. & Willis, A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat. New Biol. 231, 235-237 (1971).
8. Collier, J. G. & Flower, R. J. Effect of aspirin on human seminal prostaglandins. Lancet 2, 852-853 (1971).
9. Willis, A. L., Davison, P., Ramwell, P. W., Brocklehurst, W. E. & Smith B. in Release and Actions of Prostaglandins in Inflammation and Fever: Inhibition by Anti-inflammatory and Antipyretic Drugs (eds P. W. R. & Pharris, B. B.) (Plenum, London, 1972).
10. Robert, A., Nezamis, J. E. & Phillips, J. P. Effect of prostaglandin E1 on gastric secretion and ulcer formation in the rat. Gastroenterology 55, 481-487 (1968).
11. Flower, R., Gryglewski, R., Herbaczynska-Cedro, K. & Vane, J. R. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat. New Biol. 238, 104-106 (1972).
12. Tomlinson, R. V. & Ringold, H. J. Relationship between inhibition of prostaglandin synthesis and drug efficacy: support for the current theory on mode of action of aspirin-like drugs. Biochem. Biophys. Res. Commun. 46, 552-559 (1972).
13. Flower, R. J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol. Rev. 26, 33-67 (1974).
14. Flower, R. J. & Vane, J. R. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 240, 410-411 (1972).
15. Bhattacherjee, P. & Eakins, K. Inhibition of the PG synthetase system in ocular tissue by indomethacin. Pharmacologist 15, 209-215 (1973).
16. Flower, R. J. & Vane, J. R. in Prostaglandin Synthetase Inhibitors (eds Robinson, H. J. & J. R. V.) 9-18 (Raven, New York, 1974).
17. Marnett, L. J., Rowlinson, S. W., Goodwin, D. C., Kalgutkar, A. S. & Lanzo, C. A. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem. 274, 22903-22906 (1999).
18. Merlie, J. P., Fagan, D., Mudd, J. & Needleman, P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J. Biol. Chem. 263, 3550-3553 (1988).
19. DeWitt, D. L., el-Harith, E. A. & Smith, W. L. Molecular cloning of prostaglandin G/H synthase. Adv. Prostaglandin Thromboxane Leukot. Res. 19, 454-457 (1989).
20. Smith, W. L. & Lands, W. E. Stimulation and blockade of prostaglandin biosynthesis. J. Biol. Chem. 246, 6700-6702 (1971).
21. Roth, G. J., Stanford, N. & Majerus, P. W. Acetylation of prostaglandin synthase by aspirin. Proc. Natl Acad. Sci. USA 72, 3073-3076 (1975).
22. Roth, G. J. & Siok, C. J. Acetylation of the NH2-terminal serine of prostaglandin synthetase by aspirin. J. Biol. Chem. 253, 3782-3784 (1978).
23. Nishikawa, K., Morrison, A. & Needleman, P. Exaggerated prostaglandin biosynthesis and its influence on renal resistance in the isolated hydronephrotic rabbit kidney. J. Clin. Invest. 59, 1143-1150 (1977).
24. Morrison, A. R., Moritz, H. & Needleman, P. Mechanism of enhanced renal prostaglandin biosynthesis in ureter obstruction. Role of de novo protein synthesis. J. Biol. Chem. 253, 8210-8212 (1978).
25. Lysz, T. W. & Needleman, P. Evidence for two distinct forms of fatty acid cyclooxygenase in brain. J. Neurochem. 38, 1111-1117 (1982).
26. Whittle, B. J., Higgs, G. A., Eakins, K. E., Moncada, S. & Vane, J. R. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 284, 271-273 (1980).
27. Pash, J. M. & Bailey, J. M. Inhibition by corticosteroids of epidermal growth factor-induced recovery of cyclooxygenase after aspirin inactivation. FASEB J. 2, 2613-2618 (1988).
28. Raz, A., Wyche, A., Siegel, N. & Needleman, P. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J. Biol. Chem. 263, 3022-3028 (1988).
29. Raz, A., Wyche, A. & Needleman, P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc. Natl Acad. Sci. USA 86, 1657-1661 (1989).
30. 2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 265, 16737-16740 (1990).
31. Masferrer, J. L., Zweifel, B. S., Seibert, K. & Needleman, P. Selective regulation of cellUlar cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest. 86, 1375-1379 (1990).
32. Masferrer, J. L., Seibert, K., Zweifel, B. & Needleman, P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc. Natl Acad. Sci. USA 89, 3917-3921 (1992).
33. Wong, W. Y., DeWitt, D. L., Smith, W. L. & Richards, J. S. Rapid induction of prostaglandin endoperoxide synthase in rat preovulatory follicles by luteinizing hormone and cAMP is blocked by inhibitors of transcription and translation. Mol. Endocrinol. 3, 1714-1723 (1989).
34. Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L. & Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci. USA 88, 2692-2696 (1991).
35. Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W. & Herschman, H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266, 12866-12872 (1991).
36. Fletcher, B. S., Kujubu, D. A., Perrin, D. M. & Herschman, H. R. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J. Biol. Chem. 267, 4338-4344 (1992).
37. Kujubu, D. A. & Herschman, H. R. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J. Biol. Chem. 267, 7991-7994 (1992).
38. O'Banion, M. K., Sadowski, H. B., Winn, V. & Young, D. A. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J. Biol. Chem. 266, 23261-23267 (1991).
39. Simonson, M. S., Wolfe, J. A., Konieczkowski, M., Sedor, J. R. & Dunn, M. J. Regulation of prostaglandin endoperoxide synthase gene expression in cultured rat mesangial cells: induction by serum via a protein kinase-C-dependent mechanism. Mol. Endocrinol. 5, 441-451 (1991).
40. Farber, J. M. A collection of mRNA species that are inducible in the RAW 264.7 mouse macrophage cell line by gamma interferon and other agents. Mol. Cell Biol. 12, 1535-1545 (1992).
41. Lee, S. H. et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 267, 25934-25938 (1992).
42. O'Sullivan, M. G., Chilton, F. H., Huggins, E. M. Jr & McCall, C. E. Lipopolysaccharride priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. J. Biol. Chem. 267, 14547-14550 (1992).
43. Sirois, J., Simmons, D. L. & Richards, J. S. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthase in rat preovulatory follicles. Induction in vivo and in vitro. J. Biol. Chem. 267, 11586-11592 (1992).
44. Sirois, J. & Richards, J. S. Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles, J. Biol. Chem. 267, 6382-6388 (1992).
45. Ryseck, R. P. et al. Identification of an immediate early gene, pghs-B, whose protein product has prostaglandin synthase/cyclooxygenase activity. Cell Growth Differ. 3, 443-450 (1992).
46. Feng, L. et al. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch. Biochem. Biophys. 307, 361-368 (1993).
47. Xie, W., Merrill, J. R., Bradshaw, W. S. & Simmons, D. L. Structural determination and promoter analysis of the chicken mitogen-inducible prostaglandin G/H synthase gene and genetic mapping of the murine homolog. Arch. Biochem. Biophys. 300, 247-252 (1993).
48. Kosaka, T. et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem. 221, 889-897 (1994).
49. O'Neill, G. P. & Ford-Hutchinson, A. W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 330, 156-160 (1993).
50. Evett, G. E., Xie, W., Chipman, J. G., Robertson, D. L. & Simmons, D. L. Prostaglandin G/H synthase isoenzyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens, and oncogenes. Arch. Biochem. Biophys. 306, 169-177 (1993).
51. Kargman, S. et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111, 445-454 (1996).
52. Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J. & Vane, J. R. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl Acad. Sci. USA 90, 11693-11697 (1993).
53. Meade, E. A., Smith, W. L. & DeWitt, D. L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 268, 6610-6614 (1993).
54. DeWitt, D. L., Meade, E. A. & Smith, W. L. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal anti-inflammatory drugs. Am. J. Med. 95, S40-S44 (1993).
55. Langenbach, R. et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83, 483-492 (1995).
56. Dinchuk, J. E. et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378, 406-409 (1995).
57. Gans K. R. et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J. Pharmacol. Exp. Ther. 254, 180-187 (1990).
58. Klein, T., Nusing, R. M., Pfeilschifter, J. & Ullrich, V. Selective inhibition of cyclooxygenase 2. Biochem. Pharmacol. 48, 1605-1610 (1994).
59. Futaki, N. et al. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J. Pharm. Pharmacol. 45, 753-755 (1993).
60. Futaki, N. et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47, 55-59 (1994).
61. Crofford, L. J. et al. Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J. Clin. Invest. 93, 1095-1101 (1994).
62. Geng, Y., Blanco, F. J., Cornelisson, M. & Lotz, M. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J. Immunol. 155, 796-801 (1995).
63. Masferrer, J. L. et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl Acad. Sci. USA 91, 3228-3232 (1994).
64. Seibert, K. et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl Acad. Sci. USA 91, 12013-12017 (1994).
65. Anderson, G. D. et al. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J. Clin. Invest. 97, 2672-2679 (1996).
66. Smith, C. J. et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl Acad. Sci. USA 95, 13313-13318 (1998).
67. Zhang, Y., Shaffer, A., Portanova, J., Seibert, K. & Isakson, P. C. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J. Pharmacol. Exp. Ther. 283, 1069-1075 (1997).
68. Dirig, D. M., Isakson, P. C. & Yaksh, T. L. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats. J. Pharmacol. Exp. Ther. 285, 1031-1038 (1998).
69. Gierse, J. K. et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. 305, 479-484 (1995).
70. O'Neill, G. P. et al. Selective inhibitors of COX-2. Agents Actions Suppl. 46, 159-168 (1995).
71. Picot, D., Loll, P. J. & Garavito, R. M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367, 243-249 (1994).
72. Kurumbail, R. G. et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384, 644-648 (1996).
73. Gierse, J. K. et al. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem. 271, 15810-15814 (1996).
74. Greig, G. M. et al. The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs. Mol. Pharmacol. 52, 829-838 (1997).
75. So, O. Y., Scarafia, L. E., Mak, A. Y., Callan, O. H. & Swinney, D. C. The dynamics of prostaglandin H synthases. Studies with prostaglandin h synthase 2 Y355F unmask mechanisms of time-dependent inhibition and allosteric activation. J. Biol. Chem. 273, 5801-5807 (1998).
76. Copeland, R. A. et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl Acad. Sci. USA 91, 11202-11206 (1994).
77. Gierse, J. K., Koboldt, C. M., Walker, M. C., Seibert, K. & Isakson, P. C. Kinetic basis for selective inhibition of cyclooxygenases. Biochem. J. 339, 607-614 (1999).
78. Isakson, P., Kurumbail, R. G., Gierse, J. K., Seibert, K. & Maziasz, T. J. in Therapeutic Roles of Selective Cox-2 Inhibitors (eds Vane, J. R. & Rotting, R. M.) 48-59 (William Harvey, London, 2001).
79. Lefkowith, J. B., Verburg, K. M. & Geis, G. S. in Therapeutic Roles of Selective Cox-2 Inhibitors (eds Vane, J. R. & Setting, R. M.) 461-481 (William Harvey, London, 2001).
80. Morrison, B., Simon, T. J., DeTora, L. & Sperling, R. in Therapeutic Roles of Selective Cox-2 Inhibitors (eds Vane, J. R. & Blotting, R. M.) 541-559 (William Harvey, London, 2001).
81. Glaser, K. et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur. J. Pharmacol. 281, 107-111 (1995).
82. Tavares, I. A., Bishai, P. M. & Bennett, A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneimittelforschung 45, 1093-1095 (1995).
83. Vago, T., Bevilacqua, M. & Norbiato, G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneimittelforschung 45, 1096-1098 (1995).
84. Warner, T. D. et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl Acad. Sci. USA 96, 7563-7568 (1999).
85. Breder, C. D., Dewitt, D. & Kraig, R. P. Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol. 355, 296-315 (1995).
86. Cao, C., Matsumura, K., Yamagata, K. & Watanabe, Y. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. Brain Res. 697, 187-196 (1995).
87. Harris, R. C. et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. 94, 2504-2510 (1994).
88. Whelton, A., White, W. B., Bello, A. E., Puma, J. A. & Fort, J. G. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol. 90, 959-963 (2002).
89. Smith, C. J., Morrow, J. D., Roberts, L. J., 2nd & Marnett, F. J. Induction of prostaglandin endoperoxide synthase-1 (COX-1) in a human promonocytic cell line by treatment with the differentiating agent TPA. Adv. Exp. Med. Biol. 400A, 99-106 (1997).
90. McCarthy, D. M. Mechanisms of mucosal injury and healing: the role of non-steroidal anti-inflammatory drugs, Scand. J. Gastroenterol. Suppl. 208, 24-29 (1995).
91. Wallace, J. L., Reuter, B. K., McKnight, W. & Bak, A. Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI-safe? J. Clin. Gastroenterol. 27 Suppl 1, S28-S34 (1998).
92. Schmassmann, A. et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats. Br. J. Pharmacol. 123, 795-804 (1998).
93. Bamba, H., Ota, S., Kato, A. & Matsuzaki, F. Nonsteroidal anti-inflammatory drugs may delay the repair of gastric mucosa by suppressing prostaglandin-mediated increase of hepatocyte growth factor production. Biochem. Biophys. Res. Commun. 245, 567-571 (1998).
94. Appleton, I., Tomlinson, A., Mitchell, J. A. & Willoughby, D. A. Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation. Implications for future anti-inflammatory therapy. J. Pathol. 176, 413-420 (1995).
95. McAdam, B. F. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl Acad. Sci. USA 96, 272-277 (1999).
96. Wallace, J. L., McKnight, W., Reuter, B. K. & Vergnolle, N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119, 706-714 (2000).
97. 4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123, 1598-1606 (2002).
98. Riendeau, D. et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can. J. Physiol. Pharmacol. 75, 1088-1095 (1997).
99. Lora, M., Denault, J. B., Leduc, R. & de Brum-Fernandes, A. J. Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot. Essent. Fatty Acids, 59, 55-62 (1998).
100. Brooks, P. et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford) 38, 779-788 (1999).
101. Patrignani, P. et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 271, 1705-1712 (1994).
102. Frolich, J. C. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol. Sci. 18, 30-34 (1997).
103. Vane, J. R. & Warner, T. D. Nomenclature for COX-2 inhibitors. Lancet 356, 1373-1374 (2000).
104. Bombardier, C. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520-1528, 2 p following 1528 (2000).
105. Silverstein, F. E. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284, 1247-1255 (2000).
106. FitzGerald, G. A. & Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345, 433-442 (2001).
107. Hamberg, M. Inhibition of prostaglandin synthesis in man. Biochem. Biophys. Res. Commun. 49, 720-726 (1972).
108. Hinz, B., Kraus, V., Pahl, A. & Brune, K. Salicylate metabolites inhibit cyclooxygenase-2-dependent prostaglandin E(2) synthesis in murine macrophages. Biochem. Biophys. Res. Commun. 274, 197-202 (2000).
109. Pierce, J. W., Read, M. A., Ding, H., Luscinskas, F. W. & Collins, T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J. Immunol. 156, 3961-3969 (1996).
110. Fernandez de Arriba, A. et al. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid. Mol. Pharmacol. 55, 753-760 (1999).
111. Xu, X. M. et al. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc. Natl Acad. Sci. USA 96, 5292-5297 (1999).
112. Farivar, R. S., Chobanian, A. V. & Brecher, F. Salicylate or aspirin inhibits the induction of the inducible nitric oxide synthase in rat cardiac fibroblasts. Circ. Res. 78, 759-768 (1996).
113. Mitchell, J. A., Saunders, M., Barnes, P. J., Newton, R. & Belvisi, M. G. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol. Pharmacol. 51, 907-912 (1997).
114. Pillinger, M. H. et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc. Natl Acad. Sci. USA 95, 14540-14545 (1998).
115. Schwenger, P., Alpert, D., Skolnik, E. Y. & Vilcek, J. Cell-type-specific activation of c-Jun N-terminal kinase by salicylates. J. Cell Physiol. 179, 109-114 (1999).
116. Cronstein B. N., Montesinos, M. C. & Weissmann, G. Sites of action for future therapy: an adenosine-dependent mechanism by which aspirin retains its anti-inflammatory activity in cyclooxygenase-2 and NFκB knockout mice. Osteoarthritis Cartilage 7, 361-363 (1999).
117. Cronstein, B. N., Montesinos, M. C. & Weissmann, G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFκB. Proc. Natl Acad. Sci. USA 96, 6377-6381 (1999).
118. Chrubasik, S. et al. Treatment of low back pain exacerbations with willow bark extract: a randomized double-blind study. Am. J. Med. 109, 9-14 (2000).
119. Simmons, D. L., Botting, R. M., Robertson, P. M., Madsen, M. L. & Vane, J. R. Induction of an Acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid anti-inflammatory drugs. Proc. Natl Acad. Sci. USA 96, 3275-3280 (1999).
120. Simmons, D. L., Wagner, D. & Westover, K. Nonsteroidal anti-inflammatory drugs, acetaminophen, cyclooxygenase 2, and fever. Clin. Infect. Dis. 31 Suppl 5, S211-S218 (2000).
121. Flower, R. J. Non-steroidal anti-inflammatory drugs: back to the future. Rheumatology (Oxford) 38, 693-696 (1999).
122. Botting R. M. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin. Infect. Dis. 31 Suppl 5, S202-S210 (2000).
123. Willoughby, D. A., Moore, A. R. & Colville-Nash, P. R. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 355, 646-648 (2000).
124. Chandrasekharan, N. V. et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl Acad. Sci. USA 99, 13926-13931 (2002).
125. Martinez, R. V. at al. Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain. J. Pharm. Pharmacol. 54, 405-412 (2002).
126. Ochi, T., Motoyama, Y. & Goto, T. The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. Eur. J. Pharmacol. 391, 49-54 (2000).
127. Schwartz, J. I. et al. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin. Pharmacol. Ther. 65, 653-660 (1999).
128. Li, S. et al. The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2(-/-), but not in cyclooxygonase-1(-/-) mice. Brain Res. 825, 86-94 (1999).
129. Boutaud, O., Aronoff, D. M., Richardson, J. H., Marnett, L. J. & Oates, J. A. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. Proc. Natl Acad. Sci. USA 99, 7130-7135 (2002).
130. Ouellet, M. & Percival, M. D. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch. Biochem. Biophys. 387, 273-280 (2001).
131. Huang, H. C. et al. Diarylspiro[2. 4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationships. J. Med. Chem. 39, 253-266 (1996).
132. Li, J. J. et al. Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. J. Med. Chem. 39, 1846-1856 (1996).
133. Riendeau, D. et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121, 105-117 (1997).
134. Kalgutkar, A. S. et al. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 280, 1268-1270 (1998).
135. Kalgutkar, A. S., Kozak, K. R., Crews, B. C., Hochgesang, G. P. Jr & Marnett, L. J. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J. Med. Chem. 41, 4800-4818 (1998).
136. Kalgutkar, A. S. et al. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal anti-inflammatory drugs to potent and highly selective COX-2 inhibitors. Proc. Natl Acad. Sci. USA 97, 925-930 (2000).
137. Kalgutkar, A. S., Marnett, A. B., Crews, B. C., Remmel, R. P. & Marnett, F. J. Ester and amide derivatives of the nonsteroidal anti-inflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 43, 2860-2870 (2000).
138. DuBois, R. N., Giardiello, F. M. & Smalley, W. E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. North Am. 25, 773-791 (1996).
139. Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952 (2000).
140. Stewart, W. F., Kawas, C., Corrada, M. & Metter, E. J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632 (1997).
141. Pasinetti, G. M. & Aisen, P. S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87, 319-324 (1998).
142. Luong, C. et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Struct. Biol. 3, 927-933 (1996).
143. Bazan, N. & Flower, R. Lipid signals in pain control. Nature 420, 135-138 (2002).